Newsroom | 53340 results
Sorted by: Latest
-
Samenvatting: BeOne Medicines en Revolution Medicines kondigen samenwerking aan voor klinische ontwikkeling en regionale commercialisering
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, en Revolution Medicines, Inc. (Nasdaq: RVMD), een oncologiebedrijf dat zich in een vergevorderd stadium van klinisch onderzoek bevindt en doelgerichte therapieën ontwikkelt voor patiënten met RAS-afhankelijke kankersoorten, hebben vandaag een meerledige samenwerking aangekondigd. Deze omvat een klinisch samenwerkingsverband om combinaties te...
-
BeOne Medicines與Revolution Medicines宣布展開臨床開發與區域商業化合作
加州聖卡洛斯和加州紅木城--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)與致力於為RAS依賴性癌症病患開發標靶療法的後期臨床腫瘤公司Revolution Medicines, Inc. (Nasdaq: RVMD)今日宣布達成一項多重合作，其中包括：一項臨床合作，旨在評估將BeOne旗下若干處於臨床階段的腫瘤資產與Revolution Medicines的四種臨床RAS(ON)抑制劑之一進行聯合用藥的療效；以及一項單獨的區域權利協議，賦予BeOne在特定亞洲市場對這些Revolution Medicines資產的獨家開發與商業化權利。 此次臨床合作將探索針對RAS依賴性癌症病患的潛在標靶聯合治療方案 在此次臨床合作中，可望開發的藥物組合將包括BeOne的某些資產以及Revolution Medicines的四種臨床RAS(ON)抑制劑：daraxonrasib，一種RAS(ON)多選擇性抑制劑；zoldonrasib，一種RAS(ON) G1...
-
BeOne Medicines und Revolution Medicines kündigen Zusammenarbeit bei klinischer Entwicklung und regionaler Vermarktung an
SAN CARLOS und REDWOOD CITY, Kalifornien, USA--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, und Revolution Medicines, Inc. (Nasdaq: RVMD), ein Onkologieunternehmen mit Wirkstoffen in der späten klinischen Entwicklung, das zielgerichtete Therapien für Patienten mit RAS-abhängigen Krebserkrankungen entwickelt, gaben heute eine mehrteilige Zusammenarbeit bekannt. Diese umfasst eine klinische Zusammenarbeit zur Bewertung v...
-
BeOne Medicines et Revolution Medicines annoncent un accord de collaboration portant sur le développement clinique et la commercialisation régionale
SAN CARLOS, Californie et REDWOOD CITY, Californie--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, et Revolution Medicines, Inc. (Nasdaq : RVMD), une société d’oncologie au stade clinique avancé développant des thérapies ciblées pour les patients atteints de cancers dépendants du RAS, ont annoncé aujourd’hui une collaboration en plusieurs volets comprenant : une collaboration clinique visant à évaluer des...
-
Riassunto: BeOne Medicines e Revolution Medicines annunciano una collaborazione per lo sviluppo clinico e la commercializzazione regionale
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda globale attiva nel settore oncologico, e Revolution Medicines, Inc. (Nasdaq: RVMD), azienda operante nel settore dell'oncologia clinica in fase avanzata che sviluppa terapie mirate per pazienti affetti da tumori RAS-dipendenti, oggi ha annunciato una collaborazione articolata in più parti, che comprende una collaborazione clinica volta a valutare combinazioni di farm...
-
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). The 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously (s.c.) ev...
-
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial at the European Hematology Association (EHA) 2026 Annual Congress in J...
-
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635...
-
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution...
-
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So...
